Finance / Investment Industry Analysis

Find comprehensive market research on Pharmaceutical Finance/Investment. Be the first to predict new opportunities and spot future trends.

Change currency
The Worldwide Guide toPricing & Reimbursement (ESP00893)
Summary Provides insight into pharmaceutical pricing and reimbursement systems around the world! META Description The issues of pricing and reimbursement play an important role in determining the likely commercial success of a pharmaceutical...
Apr 2013£640€759$1,031
Big Data in Healthcare (MIC00334)
Overview: Medical data represents a large, rapidly growing, and mostly unstructured data residing in multiple locations including lab and imaging systems, physician notes, medical correspondence, claims, CRM and financial systems. With...
Apr 2013£620€736$995
Pharmaceuticals: Global Industry Guide (MKL04392)
Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals: Global Industry Guide industry. It includes detailed data on market size and segmentation, textual...
Dec 2012£930€1,103$1,495
Pharmaceuticals: Global Industry Almanac (MKL04386)
Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the...
Dec 2012£1,860€2,207$2,995
Biosensors - A Global Market Overview (INX00030)
An increase in the number of applications for biosensors developed or being developed has ensured that this technology follows a growth curve, leading to standardization of equipment, type of biomolecule,...
Mar 2012£2,515€2,984$4,050
Biobetters: Major Players and Market Prospects (2nd edition) (FWD00014)
Marketing gimmick or natural evolution? For some, biobetters-drugs similar but superior to the branded reference product-are little more than the natural outcome of a drug's life-cycle management strategy. Even so, interest in...
Sep 2011£355€421$572
REMS: A Standardized Approach to Risk Management (FWD00031)
Risk Evaluation and Mitigation Strategies. Until recently, the Federal Drug Administration's REMS program impacted drugs that would not have been otherwise approved due to their risks. The hurdles, costs and additional...
Sep 2010£295€350$475
Pricing & Reimbursement in Emerging Markets (DAT22818)
Analysis of pricing mechanisms and the influence of public and private sector health insurance provisionOver the past few years, pharmaceutical sales in the emerging markets have regularly been growing at double-digit rates, albeit in some of the markets there has been a temporary blip...
Aug 2010£2,380€2,824$3,835
The Funding Landscape for Small Biopharma Ventures, 2010-2015 (DAT22816)
Trends, strategies and prioritiesThe funding landscape for small and mid-cap biomedical companies has changed enormously over the past two years, driven by recessive public markets and withdrawal of private equity financing. The cost...
Jul 2010£2,380€2,824$3,835
Pharma's Leaking 4.4% of Revenue Annually (IDC08141)
This IDC Health Insights Perspective discusses preliminary results from our research on revenue leakage in the life sciences. The full report is due out in December 2009.
Dec 2009£930€1,103$1,500
Healthcare Stakeholders in Latin America (FWD00013)
Secrets of Engagement Twenty countries Three languages Seven racial groups And an estimated population of 623 million people by 2030 By anyone's measure, Latin America is one of the most ethnically diverse and economically complex regions on...
Dec 2009£235€279$379
Life Sciences Funding (FRS00657)
2008This Frost & Sullivan research service titled Life Sciences Funding - 2008 provides an overview of the current funding scenario in Europe, budget allocations of various funding bodies in the...
Dec 2009£4,035€4,787$6,500
Business Strategy: Revenue Leakage — Pharma's $11 Billion Problem (IDC08556)
This Health Industry Insights report examines process inefficiencies surrounding claims management and drug reconciliation within the pharmaceutical sales channel, and discusses the primary pain points causing revenue loss. Questions answered...
Dec 2009£2,795€3,316$4,500
Business Trends: Pharmaceuticals Technology Understanding Your Life Sciences Customer, 2009 (Customer Focus) (DAT17460)
TechnologyIntroduction This Ovum study examines top business challenges, IT budget outlook, and spending priorities among pharmaceutical and biotechnology companies in the US, Canada, the UK, France, Germany, Japan, China and India....
Nov 2009£2,110€2,503$3,395
Investment Patterns in the Healthcare Industry- An Analysis (FRS01223)
This research study examines the various investments that have happened in the healthcare industry over the years 2008-2009. The investments are broadly classified as Equity, Debt and Loans. The study...
Sep 2009£3,725€4,420$6,000
Pharma Corporate Venture Capital (CVC): key players, new conditions and big opportunities (FWD00007)
A good opportunity is opening up for pharma CVCs, but only if the corporate structure is right The medical/health and life science sector was the second highest corporate venture capital (CVC)...
Sep 2009£295€350$475
Business Strategy: Western European, Healthcare Sector Spending 2008–2012 Special Update (IDC09243)
In this Health Industry Insights report, we provide an overview of IT spending trends and forecasts in the Western European healthcare sector. On the quantitative side, focus is on spending...
May 2009£6,210€7,368$10,000
Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape (DAT14042)
Introduction Since the financial meltdown, the relationship between Pharma and Biotech has been turned on its head. Previously, pharma companies had no choice but to license Biotech drugs at high prices...
Dec 2008£2,360€2,800$3,800
Financial Markets Research: Palatin Technologies\' Bremelanotide (DAT19523)
Competition and regulatory risk cloud potentialIntroduction Palatin Technologies' bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and...
Sep 2006£1,365€1,620$2,195
Financial Markets Research: Sirona Dental Systems (DAT19526)
Likely struggle for impressive annual growth despite strong reputation and technologyIntroduction Digital imaging products and CEREC form the basis for growth for Sirona Dental Systems, while accounting for nearly two-thirds of revenues, and will therefore be essential to the newly formed...
Sep 2006£1,365€1,620$2,195
Financial Markets Research: Spectrum Pharmaceuticals\' Oral Satraplatin (DAT19527)
Oral therapy to take share in second-line hormone-refractory prostate cancer marketIntroduction There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which...
Sep 2006£1,365€1,620$2,195
Financial Markets Research: Santarus, Inc.\'s Zegerid (DAT19525)
Fast-acting formulation gaining momentum in GERDIntroduction Following the lackluster 2004 launch of an oral suspension formulation of Santarus' lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus' future success is tied to the commercial...
Aug 2006£1,365€1,620$2,195
Financial Markets Research: Renovis, Inc.\'s NXY-059 (DAT19524)
Safety profile and unmet need could drive approvalIntroduction Renovis and AstraZeneca's NXY-059 is viewed as the most promising neuroprotectant currently in development for stroke, however, much of its potential is dependent upon its ability to demonstrate a benefit...
Aug 2006£1,365€1,620$2,195
Financial Markets Research: Endo Pharmaceuticals’ Lidoderm (DAT19521)
Physician survey indicates increased use likely to fuel above-consensus sales growthIntroduction Surveyed physicians expect to continue to increase their use of Lidoderm in post-herpetic neuralgia and a variety of off-label pain conditions with use varying by specialty.The largest barriers to use...
Aug 2006£1,365€1,620$2,195
Financial Markets Research: ASCO Review Part II (DAT19519)
A summary of highlights presented at the ASCO 2006 Annual MeetingIntroduction ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor's comments on the most important events at the...
Aug 2006£1,365€1,620$2,195